Ongoing and future trials will attempt to demonstrate the benefi t of NK cell therapies in lymphomas, multiple myeloma, sarcomas, and glioblastoma multiforme, among others.
In December, I spent time in beautiful San Diego at the annual meeting of the American Society of Hematology (ASH). During the meeting, but from a different city in Southern California, the nominees for the 81st annual Golden Globe Awards were announced, with Barbie and Oppenheimer each scoring many nominations. With Hollywood’s awards season approaching, I ask myself, “Who should win the award for the most inspiring lecture given at ASH?” And I know immediately who would get my vote.
The award for the most inspiring lecture at ASH goes to…Katy Rezvani, MD, PhD, who gave a lecture entitled “Natural Killer Cells: A New Frontier for Cancer Immunotherapy,” as she accepted the E. Donnall Thomas Lecture and Prize. Dr Rezvani provided a masterful explanation of how her current work to develop natural killer (NK) cell therapies evolved from decades of research into bone marrow transplantation, graft-vs-leukemia effect, chimeric antigen receptor (CAR) T-cell therapy, and NK cell biology.
NK cell therapies have tremendous promise to treat cancer, both liquid and solid. They have on their surfaces receptors that permit differentiation of normal from abnormal cells. NK cells offer several potential advantages over T cells as therapies for cancer. The killing of target cells can be mediated not only by the transduced CAR but also by endogenous receptors on the NK cell surface. The presence of CD16 on their surface is critical for antibody-dependent cellular cytotoxicity. Allogeneic NK cells do not cause graft-vs-host disease. Many therapeutic doses can be manufactured from a single donor, thereby lowering cost and permitting “off the shelf” availability. NK cells have a favorable adverse effect profile, as they do not cause cytokine release syndrome or neurological toxicity.
Development of NK cell therapies has not been without challenges, of course. NK cells survive for only about a week if given without exogenous support. The quality of NK cells from different donors can vary. How best to modify NK cells to permit maximum killing of target tumor cells remains a work in progress; success will require determining the most effective combination of CARs and endogenous antigens on the surface of the NK cells.
Ongoing and future trials will attempt to demonstrate the benefi t of NK cell therapies in lymphomas, multiple myeloma, sarcomas, and glioblastoma multiforme, among others.
Advances in Subsequent Therapies Shake Up Sequencing of ccRCC Treatment
April 25th 2024With the approval of belzutifan and other newer data for treating patients with recurrent renal cell carcinoma, the state of subsequent therapies is advancing beyond the reuse of frontline options with impacts on duration of response and quality of life.
Read More
Novel Approaches Focus on Limiting Toxicity in Older Patients With ALL
April 22nd 2024The major challenges for clinicians treating older patients with acute lymphoblastic leukemia surround the emergence of resistance to existing therapies and the toxicities associated with current chemotherapies.
Read More
Ornstein Advises on Starting Dose and Management of Lenvatinib in RCC
April 21st 2024During a Case-Based Roundtable® event, Moshe Ornstein, MD, MA, provided guidance on dosing and toxicity concerns in a patient treated with lenvatinib plus pembrolizumab for advanced renal cell carcinoma.
Read More